10-Q: Microbot Medical Q1 2026 Financial Results

Microbot Medical reports Q1 2026 revenue of $105,000 as it transitions from development to commercialization of its LIBERTY Endovascular Robotic System.

Summary

• Reported revenue of $105,000 for Q1 2026, marking the start of commercial operations.
• Net loss for the quarter was $3.67 million, compared to a $2.60 million loss in Q1 2025.
• Operating loss increased to $4.32 million from $3.02 million in the prior year period.
• Cash and marketable securities totaled approximately $72.5 million as of March 31, 2026.
• Full market release of the LIBERTY Endovascular Robotic System commenced in April 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral-to-positive development; while losses have increased, the transition to commercial revenue and a strong cash position provide a stable foundation for growth.

Positives

• Successfully transitioned to commercial operations with the first revenue generation from the LIBERTY system.
• Strong liquidity position with approximately $72.5 million in cash and marketable securities.
• FDA 510(k) clearance received for the LIBERTY Endovascular Robotic System in September 2025.
• ISO 13485:2016 certification achieved, supporting future regulatory approvals.

Negatives

• Net loss widened to $3.67 million, driven by increased commercialization and payroll expenses.
• Operating expenses rose significantly due to new hiring and commercial activities.
• Absence of non-recurring other income (which provided $316,000 in Q1 2025) impacted the bottom line.
• Continued reliance on external capital to fund operations.

Risks

• Ongoing regional armed conflict in the Middle East involving Israel, Iran, and the U.S. could disrupt operations.
• Potential for supply chain disruptions, including the import of materials and shipping of devices out of Israel.
• Uncertainty regarding the ability to raise additional capital on favorable terms.
• Dependence on successful commercial adoption of the LIBERTY system in a competitive market.
• Regulatory risks associated with future CE Mark approval and ongoing FDA compliance.

Future Outlook

The company expects to continue incurring significant losses as it ramps up manufacturing and commercialization of the LIBERTY system. Management believes current funds are sufficient for at least 12 months and anticipates CE Mark approval in the second half of 2026.

Management Comments

• Management believes available funds are sufficient to fund operations for more than twelve months.
• The company is closely monitoring the Middle East conflict for potential impacts on clinical, regulatory, and operational activities.

Industry Context

StockSavvy.ai notes that Microbot is entering a highly competitive surgical robotics space. The shift from R&D to commercialization is a critical inflection point, though the company remains vulnerable to geopolitical instability in Israel, which serves as its primary R&D hub.

Comparison to Industry Standards

• The company's 'disposable' robotic model differentiates it from traditional capital-intensive systems like Intuitive Surgical's da Vinci.
• The focus on peripheral vasculature places it in competition with established players in the interventional radiology space.

Corporate Governance

Legal Proceedings

• The company successfully resolved a Section 16(b) litigation against Alliance Investment Management, Ltd. and Joseph Mona in 2025.
• An employment-related discrimination charge filed with the MCAD/EEOC was dismissed in May 2026.

Stakeholder Impact

• Shareholders face potential dilution from future capital raises and the exercise of outstanding warrants.
• Customers (hospitals) are beginning to adopt the LIBERTY system.

Next Steps

• Continue full market release of the LIBERTY Endovascular Robotic System.
• Pursue CE Mark approval, anticipated in the second half of 2026.
• Explore autonomous robotics integration with Emory University.

Key Dates

Recommendation

The company is in a high-risk, high-reward phase. While the technology is promising and the balance sheet is strong, the transition to commercial success is unproven and geopolitical risks remain significant.

Keywords

Microbot Medical, MBOT, Surgical Robotics, Endovascular, Medical Devices, LIBERTY System, Minimally Invasive Surgery